Recently, DCAT Week 2026. an annual event with great influence in the global biopharmaceutical field, was grandly held in New York, USA. As a communication platform in the fields of global pharmaceutical supply chain and R&D & manufacturing services, this edition of the exhibition gathered enterprises, technology suppliers and industry decision-makers from dozens of countries and regions around the world, conducting in-depth exchanges and cooperation negotiations on core topics such as API R&D, formulation production, full-industry-chain CDMO services, green pharmaceuticals, and industrial collaborative innovation. Laviana Pharma made a high-profile appearance with its one-stop innovative pharmaceutical CDMO full-process solution package.

During the conference, Laviana Pharma comprehensively demonstrated its full-chain CDMO service capabilities—spanning drug discovery, process development, clinical-stage sample production, and commercial-scale manufacturing—in its exclusive meeting room at the InterContinental New York Barclay Hotel in New York. The company highlighted its core technological strengths such as small-molecule innovative drug R&D, high-activity active pharmaceutical ingredient (API) production, green synthesis processes, and compliance-based quality control, while also presenting the outcomes of its global capacity and R&D layout, including the Cangzhou GMP production base and Tianjin R&D center.

At the conference site, team of Laviana Pharma from North America for technology and business held one-to-one in-depth discussions with representatives from many well-known pharmaceutical enterprises, biotechnology companies and industry institutions across the globe. In response to core needs of global customers in shortening of drug research and development cycle, control of production cost, upgrade of quality compliance and sustainable development, team of Laviana Pharma gave detailed interpretation of customized research and manufacturing solutions of the enterprise, shared successful cases in fields such as synthesis of complex drug molecules and translation of industrialization technologies, and fully demonstrated core competitiveness of the enterprise in aspects like technological innovation, assurance of production capacity and global compliance services. Many international customers spoke highly of one-stop CDMO service model of Laviana Pharma, strict quality control system and concept of green pharmaceuticals, and reached preliminary cooperation consensus on multiple projects for research and development of innovative drugs and commercial production of active pharmaceutical ingredients on the spot.

As a technology-driven innovative pharmaceutical CDMO enterprise, Laviana Pharma has since establishment in 2003 consistently adhered to development philosophy of "Become a flagship CDMO enterprise", continuously increased investment in research and development and manufacturing, and improved global capacity and service network. In recent years, enterprise successively obtained EcoVadis gold certification and ISO series international management system certifications, possesses core capacity facilities such as CNAS laboratory and high-activity production line, and achievements in research and development and quality of service have gained wide recognition from global market.

The appearance of Laviana Pharma at DCAT Week 2026 is another important milestone of globalization strategy layout of Laviana Pharma, which not only further enhances brand awareness and influence of the enterprise in mainstream pharmaceutical markets of Europe and the United States, but also builds a high-quality bridge for communication and cooperation between innovative forces of Chinese pharmaceuticals and global industry partners.